k Risankizumab autoinjector for psoriasis treatment Hand holding a risankizumab autoinjector pen. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A IL23A and blocks the activity of proinflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis., by DR P. MARAZZISCIENCE PHOTO LIBRARY Stock Photo - Afloimages
Sign up
Login
All images
Risankizumab autoinjector for psoriasis treatment Hand holding a risankizumab autoinjector pen. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A  IL 23A  and blocks the activity of pro inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis., by DR P. MARAZZI SCIENCE PHOTO LIBRARY
RM

Risankizumab autoinjector for psoriasis treatment

Hand holding a risankizumab autoinjector pen. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis., by DR P. MARAZZI/SCIENCE PHOTO LIBRARY

Details

ID
250408941

Collection

License type
Rights Managed

Photographer



Sign in
Member access
Login not found.